Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of Antivenin Against Vipera Russelli Siamensis in patients with Vipera russelli siamensis (round-spotted viper) bites
CTR20240299Phase 2Active
- Sponsor
- Shanghai Serum Bio-Technology
- Start
- Feb 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antivenin against vipera russelli siamensis in snakebite, sponsored by Shanghai Serum Bio-Technology. Started Feb 2024; status: active.
02
Drugs
antivenin against vipera russelli siamensis
03
Conditions
snakebite
Beyond the preview
Go deeper on CTR20240299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240299.